My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Eli Lilly (NY:LLY)

1,142.81 -14.27 (-1.23%)

Delayed Quote Updated: 12:21 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy ↗

September 30, 2026

Could this be what Novo needs to turn things around?

Via The Motley Fool

Topics Initial Public Offering

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. ↗

September 30, 2026

There could be more catalysts for the biotech over the next 18 months.

Via The Motley Fool

2 Outstanding Dividend Stocks to Buy and Hold for a Decade ↗

September 30, 2026

There is probably no dividend cut on the horizon for these healthcare companies.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly (NYSE:LLY) Offers a Breakout Setup Backed by High Growth Momentum ↗

September 28, 2026

Via Chartmill

3 Emerging Biotech Stocks With Significant Upside Potential ↗

September 30, 2026

Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.

Via MarketBeat

Topics Intellectual Property

Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug ↗

September 30, 2026

Eli Lilly already beat its next-generation weight-loss drug, retatrutide, and it hasn't even hit the market.

Via Investor's Business Daily

Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market. ↗

September 30, 2026

Phase three trials on Eli Lilly's new weight loss drug, TRIUMPH-2, showed strong results.

Via The Motley Fool

Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market? ↗

September 30, 2026

Roche is increasingly looking like a notable contender in this fast-growing area.

Via The Motley Fool

4 Stocks That Could Split Next—and Why Investors Are Watching ↗

September 30, 2026

AutoZone, Eli Lilly, Meta Platforms, and Costco all trade at high share prices, making them candidates for stock splits as analysts raise price targets and cite strong fundamentals.

Via MarketBeat

Topics Artificial Intelligence

Meet the Low-Cost Vanguard ETF With 51.8% Invested in Nvidia, Apple, Alphabet, Microsoft, and Amazon While VOO Has Just 30% ↗

September 30, 2026

The Vanguard Morningstar Mega Cap Growth ETF offers concentrated exposure across the artificial intelligence (AI) value chain.

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

3 Undervalued Healthcare Stocks Invstors Can Buy Right Now ↗

September 29, 2026

Consumer spending on healthcare is relatively more stable compared to most other industries.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly Might Be the Next Stock I Buy ↗

September 29, 2026

The company has a history of developing treatments that have achieved widespread adoption.

Via The Motley Fool

Opinion: Eli Lilly Stock Is a No-Brainer Pick to Buy on the Dip ↗

September 29, 2026

This stock is worth loading up on whenever it's on the cheap side.

Via The Motley Fool

Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 29, 2026

Bristol Myers Squibb trades at a fraction of Eli Lilly's valuation while generating substantial free cash flow, but concentration risk and explosive growth tell very different stories.

Via The Motley Fool

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. ↗

September 29, 2026

Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.

Via The Motley Fool

Want a $1 Million Investment Portfolio? History Says This Strategy Could Get You There. ↗

September 29, 2026

Consistency is one of the biggest factors in making it happen.

Via The Motley Fool

Topics ETFs Economy

2026 Nanocap Stocks to Watch: IGC, KNRX, GYGY, ARAY Lead Watchlist Now See More Inside!

September 28, 2026

Via AB Newswire

Topics Artificial Intelligence

VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs

September 28, 2026

Via AB Newswire

2 of the Best ETFs to Buy When Inflation Is Running Hot ↗

September 28, 2026

Higher inflation rates have caused investors to rethink their portfolios.

Via The Motley Fool

Topics ETFs Economy

Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly? ↗

September 28, 2026

Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.

Via The Motley Fool

Eli Lilly Just Announced Game-Changing News ↗

September 28, 2026

Something new is happening in the weight loss drug market.

Via The Motley Fool

Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution ↗

September 27, 2026

The company recently delivered some exciting trial data, but it also needs to deliver in the second part of the trial.

Via The Motley Fool

Here's Where Wall Street Analysts See Eli Lilly's Share Price Going ↗

September 26, 2026

Eli Lilly's share price climb has decelerated in 2026.

Via The Motley Fool

Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become ↗

September 26, 2026

Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.

Via The Motley Fool

Topics Intellectual Property

Guess Which Group of Stocks Is Back at an All-Time High? ↗

September 26, 2026

The "Magnificent Seven" ETF finally topped the record high it set in May.

Via The Motley Fool

Topics Artificial Intelligence ETFs Electric Vehicles

MarketBeat Week in Review – 09/21 - 09/25 ↗

September 26, 2026

A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm.

Via MarketBeat

Topics Artificial Intelligence Bonds Economy

Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product? ↗

September 25, 2026

The drugmaker badly needs more clinical wins.

Via The Motley Fool

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? ↗

September 25, 2026

The biotech player could eventually rival big pharma companies.

Via The Motley Fool

2 Healthcare Stocks with Impressive Fundamentals and 1 Facing Challenges

September 25, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...

Via StockStory

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? ↗

September 24, 2026

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.